HBM Holdings (FRA:6XY) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6XY HBM Holdings Ltd FRA:6XY
62 GF Score
Price €1.35
GF Value €0.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is HBM Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of HBM Holdings is: High Risk: High uncertainty with risk-return tradeoff.

HBM Holdings  (FRA:6XY) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

HBM Holdings Risk Assessment Related Terms

FRA:6XY vs VRTX, REGN, RVMD: Risk Assessment Comparison

For the Biotechnology subindustry, HBM Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Risk Assessment falls into.


FRA:6XY
62GF Score
HBM Holdings Ltd FRA:6XY
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HBM Holdings (FRA:6XY) Overvalued in 2026?

Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued. The current stock price of €1.35 is trading 80% above its estimated GF Value™ of €0.75. GuruFocus considers HBM Holdings to be Significantly Overvalued.

Key valuation signals for FRA:6XY:

  • Risk Assessment:
  • GF Value™: €0.75 vs. price of €1.35 (80% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HBM Holdings Business Description

Other Exchanges 02142:Hong Kong
Address No. 388 Fenglin Road, 6th Floor, Tower B, Fenglin International Phase I, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
62GF Score

Get the complete analysis for FRA:6XY

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.35
Price
€0.75
GF Value